Research has shown that the use of biologic therapies, particularly TNF-α inhibitors, offers benefits beyond cutaneous control in patients with psoriasis, including a significant reduction in the incidence of cardiovascular events, such as acute myocardial infarction. The gene discussed is TNF; the disease is psoriasis.